Calling the National Cancer Institute

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

WASHINGTON--Up to one-third of callers to the National Cancer Institute’s hot line for cancer information(1-800-4-CANCER) get a busy signal or hang up because of the long wait for someone to pick up, according to a report by the inspector general of the Department of Health and Human Services.

WASHINGTON--Up to one-third of callers to the National Cancer Institute’s hot line for cancer information(1-800-4-CANCER) get a busy signal or hang up because of the long wait for someone to pick up, according to a report by the inspector general of the Department of Health and Human Services.

The wait can be as long as 20 minutes. This year it is averaging 5.3 minutes, down from an average of 7.2 minutes last year, said Cristy Thomsen, chief of the NCI’s Cancer Information Service. Ms. Thomsen agreed to many of the inspector general’s recommendations, and said the NCI plans to address the problems.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content